Sotera Health(SHC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total company revenue increased by 5.7% to $1.164 billion in 2025, or 5.2% growth on a constant currency basis compared to 2024 [5][15] - Adjusted EBITDA rose by 8.2% to $593.8 million, with adjusted EBITDA margins expanding to 51%, an increase of 118 basis points [5][15] - Adjusted free cash flow exceeded $200 million in 2025 [5] - For Q4 2025, total revenues increased by 4.6% to $303 million, or 2.5% on a constant currency basis [11] Business Line Data and Key Metrics Changes - Sterigenics revenue improved by 10.6% to $198 million, driven by favorable pricing and volume [12] - Nordion's revenue decreased by 12.3% to $50 million due to unfavorable volume and mix from Cobalt-60 harvest timing [13] - Nelson Labs revenue increased by 2.3% to $55 million, with favorable pricing partially offset by lower expert advisory services revenue [14] Market Data and Key Metrics Changes - Customer satisfaction exceeded 80%, indicating strong service delivery [6] - Revenue from XBU customers expanded by 9% year-over-year [6] Company Strategy and Development Direction - The company is focused on executing its 2025-2027 long-range plan, with expectations for continued growth and operational excellence [8] - The strategic decision to enhance the X-ray facility is aimed at expanding service offerings across all modalities [44][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive long-term growth and shareholder value, emphasizing strong cash flow and customer relationships [21] - The guidance for 2026 anticipates total revenue growth to a range of $1.233 billion-$1.251 billion, representing 5%-6.5% constant currency growth [9][18] Other Important Information - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in annual interest savings of $13 million [7] - A management transition was announced, with Erika Ostrowski promoted to Senior Vice President and General Counsel [10] Q&A Session Summary Question: Guidance and EBITDA margins - The midpoint of the guidance implies about 20 basis points of expansion, driven by normal operating leverage [23][24] Question: Sterigenics client insourcing - Management noted that while one client is transitioning back to outsourcing, significant shifts are not expected at this time due to regulatory compliance timelines [25][26] Question: 2026 outlook for Sterigenics - Expected mid to high single-digit constant currency revenue growth for Sterigenics in 2026, with a soft start anticipated in Q1 [32][42] Question: Nelson Labs margins - Nelson Labs is expected to maintain margins in the low to mid-30s, with Q1 being the lightest quarter [34][35] Question: Nordion segment headwinds - Revenue challenges were attributed to Cobalt-60 harvest timing rather than demand issues [84][85] Question: Competitive positioning in Sterigenics - Management indicated that while NESHAP compliance discussions are ongoing, the urgency has decreased due to extended deadlines [68][69] Question: Impact of tariffs and onshoring - The company has not seen significant impacts from tariffs or onshoring trends, maintaining a strong market position [87][88]